Xeris Biopharma Holdings Inc’s recently made public that its Director Schmid John P. acquired Company’s shares for reported $10147.0 on Aug 12 ’24. In the deal valued at $2.25 per share,4,515 shares were bought. As a result of this transaction, Schmid John P. now holds 25,200 shares worth roughly $90972.0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Schmid John P. bought 4,285 shares, generating $10,134 in total proceeds. Upon buying the shares at $2.37, the Director now owns 20,685 shares.
Before that, Schmid John P. bought 5,400 shares. Xeris Biopharma Holdings Inc shares valued at $10,314 were divested by the Director at a price of $1.91 per share. As a result of the transaction, Schmid John P. now holds 16,400 shares, worth roughly $59204.0.
Piper Sandler downgraded its Xeris Biopharma Holdings Inc [XERS] rating to a Neutral from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in late March with a ‘”an Outperform”‘ rating. Craig Hallum began covering XERS with “Buy” recommendation on August 28, 2023. Jefferies started covering the stock on October 21, 2022. It rated XERS as “a Buy”.
Price Performance Review of XERS
On Monday, Xeris Biopharma Holdings Inc [NASDAQ:XERS] saw its stock fall -1.63% to $3.61. Over the last five days, the stock has gained 6.80%. Xeris Biopharma Holdings Inc shares have risen nearly 53.62% since the year began. Nevertheless, the stocks have risen 86.08% over the past one year. While a 52-week high of $3.87 was reached on 12/06/24, a 52-week low of $1.69 was recorded on 04/26/24. SMA at 50 days reached $3.15, while 200 days put it at $2.52.
Levels Of Support And Resistance For XERS Stock
The 24-hour chart illustrates a support level at 3.55, which if violated will result in even more drops to 3.49. On the upside, there is a resistance level at 3.71. A further resistance level may holdings at 3.81. The Relative Strength Index (RSI) on the 14-day chart is 64.18, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.34, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 25.74%. Stochastics %K at 84.01% indicates the stock is a selling.
How much short interest is there in Xeris Biopharma Holdings Inc?
A steep rise in short interest was recorded in Xeris Biopharma Holdings Inc stocks on 2024-11-15, dropping by -1.42 million shares to a total of 10.15 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 11.57 million shares. There was a decline of -13.98%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 28, 2022 when Craig Hallum began covering the stock and recommended ‘”a Buy”‘ rating along with a $6.50 price target.
